RefleXion Announces Todd Powell Named to Top 50 Healthcare Technology CEOs of 2022

May 13, 2022

HAYWARD, Calif., May 13, 2022 – RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT)* for all stages of cancer, is pleased to announce that Todd Powell, president and CEO, has been recognized by the Healthcare Technology Report as one of the Top 50 Healthcare Technology CEOs of 2022.

This year’s awardees represent some of the most accomplished executives in healthcare technology. Their leadership has been critical in developing industry leading medical devices and next generation software platforms.

“Todd has built a reputation for excellence with a career that spans more than 30 years in oncology, including leading global organizations and developing innovative products in cancer care. I cannot think of a better individual to be at the helm.”

Sam Mazin, Ph.D.
Founder and CTO

“Todd’s impact on RefleXion has been nothing short of profound, and it’s just wonderful to see him recognized for his exemplary leadership and considerable success in growing our company,” said Sam Mazin, Ph.D., founder and CTO for RefleXion. “Todd has built a reputation for excellence with a career that spans more than 30 years in oncology, including leading global organizations and developing innovative products in cancer care. I cannot think of a better individual to be at the helm.”

Powell has successfully led commercialization of RefleXion’s first product, the RefleXion® X1, that has delivered over 2,500 patient treatments, while driving completion of its first clinical study and initiation of a real-world evidence clinical registry for patients with all stages of cancer. Furthermore, he has raised over $375M to grow the company from 60 to 300 employees, since assuming his role in 2017.

Moreover, under Powell’s leadership, and unique to the industry, RefleXion has strategic relationships with leading pharmaceutical companies, prompting several to invest substantially in RefleXion, and others to enter into collaboration agreements to further develop its flagship BgRT technology.

The complete profile and full list of 2022’s Top 50 Healthcare Technology CEOs are available here.

About RefleXion Medical

RefleXion is a privately-held company developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency.

*The RefleXion® X1 is cleared for SBRT/SRS/IMRT. BgRT is pending regulatory review and is not commercially available.

# # #

Media Contact

Amy Cook
acook@reflexion.com
925-200-2125